Hepatitis E virus: Neutralizing sites, diagnosis, and protective immunity

Reviews in Medical Virology

Volumn 22, Issue 5, 2012, Pages 339-349

  Zhang, Jun ^a   Li, Shao Wei ^a   Wu, Ting ^a   Zhao, Qinjian ^a   Ng, Mun Hon ^a   Xia, Ning Shao ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; EPITOPE; HECOLIN; HEPATITIS E VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; RECOMBINANT HEPATITIS E VACCINE; UNCLASSIFIED DRUG; VIRUS RNA;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; CHINA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; EPIDEMIC; EXPERIMENTAL INFECTION; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFECTION RATE; NONHUMAN; REVIEW; SANITATION; VACCINATION; VIROLOGY; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; EPITOPES; HEPATITIS ANTIBODIES; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRAL HEPATITIS VACCINES;

EID: 84865756039     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1719     Document Type: Review

References (89)

1. Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clinical Infectious Diseases 2010; 51: 328-334.
2. Purcell RH, Emerson SU. Prevention. In Viral Hepatitis, 3rd edn, Thomas HC, Lemon S, Zuckerman AJ (eds). Blackwell Publishing: Malden, MA, 2005; 635-645.
3. World Health Organization South-East Asia Region. Viral Hepatitis in the WHO South-East Asia Region. March 11, 2012, date last accessed. Available from: URL: http://www.searo.who.int/LinkFiles/Diarrhoea _ARI_and_hepatitis_SEA-CD-232.pdf
4. Emerson SU, Anderson D, Arankalle VA. Hepevirus. In Virus Taxonomy. VIIIth Report of the ICTV, Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds). Elsevier/Academic Press: London, 2004; 851-855.
5. Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 8259-8263.
6. Zafrullah M, Ozdener MH, Panda SK, Jameel S. The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. Journal of Virology 1997; 71: 9045-9053.
7. Panda SK, Thakral D, Rehman S. Hepatitis E virus. Reviews in Medical Virology 2007; 17: 151-180.
8. Tyagi S, Korkaya H, Zafrullah M, Jameel S, Lal SK. The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2. Journal of Biological Chemistry 2002; 277: 22759-22767.
9. Tyagi S, Surjit M, Lal SK. The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a Kunitz-type serine protease inhibitor. Journal of Virology 2005; 79: 12081-12087.
10. Tyagi S, Surjit M, Roy AK, Jameel S, Lal SK. The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. Journal of Biological Chemistry 2004; 279: 29308-29319.
11. Yamada K, Takahashi M, Hoshino Y, et al. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. Journal of General Virology 2009; 90: 1880-1891.
12. Chandra V, Kalia M, Hajela K, Jameel S. The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the Cbl-CIN85 complex. Journal of Virology 2010; 84: 3857-3867.
13. Takahashi M, Yamada K, Hoshino Y, et al. Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Archives of Virology 2008; 153: 1703-1713.
14. Kamili S. Toward the development of a hepatitis E vaccine. Virus Research 2011; 161: 93-100.
15. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Reviews in Medical Virology 2006; 16: 5-36.
16. Hakze-van der Honing RW, van Coillie E, Antonis AF, van der Poel WH. First isolation of Hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium. PLoS One 2011; 6: e22673.
17. Meng XJ. Hepatitis E Virus: animal reservoirs and zoonotic risk. Veterinary Microbiology 2010; 140: 256-265.
18. Wibawa ID, Suryadarma IG, Mulyanto, et al. Identification of genotype 4 hepatitis E virus strains from a patient with acute hepatitis E and farm pigs in Bali, Indonesia. Journal of Medical Virology 2007; 79: 1138-1146.
19. Xu K, Wang A, Zhang J, et al. An outbreak of hepatitis E among aged people in a nursing home. Chinese Journal of Zoonoses 2012; 28: 115-119.
20. Sanford BJ, Dryman BA, Huang YW, Feagins AR, Leroith T, Meng XJ. Prior infection of pigs with a genotype 3 swine hepatitis E virus (HEV) protects against subsequent challenges with homologous and heterologous genotypes 3 and 4 human HEV. Virus Research 2011; 159: 17-22.
21. Xing L, Kato K, Li T, et al. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T=1 particle presenting native virus epitopes. Virology 1999; 265: 35-45.
22. Li TC, Takeda N, Miyamura T, et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. Journal of Virology 2005; 79: 12999-13006.
23. Xing L, Li TC, Mayazaki N, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. Journal of Biological Chemistry 2010; 285: 33175-33183.
24. Guu TS, Liu Z, Ye Q, et al. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 12992-12997.
25. Yamashita T, Mori Y, Miyazaki N, et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 12986-12991.
26. Li S, Tang X, Seetharaman J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathogens 2009; 5: e1000537.
27. Li SW, Zhang J, He ZQ, et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. Journal of Biological Chemistry 2005; 280: 3400-3406.
28. Tang X, Yang C, Gu Y, et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 10266-10271.
29. Zhang J, Gu Y, Ge SX, et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005; 23: 2881-2892.
30. Zhang J, Ge SX, Huang GY, et al. Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. Journal of Medical Virology 2003; 71: 518-526.
31. Li SW, Zhang J, Li YM, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23: 2893-2901.
32. Bryan JP, Tsarev SA, Iqbal M, et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. Journal of Infectious Diseases 1994; 170: 517-521.
33. Tsarev SA, Tsareva TS, Emerson SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 10198-10202.
34. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999; 286: 287-290.
35. Dong J, Dong L, Mendez E, Tao Y. Crystal structure of the human astrovirus capsid spike. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 12681-12686.
36. Pokidysheva E, Zhang Y, Battisti AJ, et al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 2006; 124: 485-493.
37. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
38. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371: 37-43.
39. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-183.
40. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-711.
41. Im SW, Zhang JZ, Zhuang H, et al. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus. Vaccine 2001; 19: 3726-3732.
42. Purdy MA, McCaustland KA, Krawczynski K, et al. Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recognized by antibodies in sera from human cases and experimentally infected primates. Archives of Virology 1992; 123: 335-349.
43. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. The New England Journal of Medicine 2007; 356: 895-903.
44. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.
45. Schofield DJ, Glamann J, Emerson SU, Purcell RH. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. Journal of Virology 2000; 74: 5548-5555.
46. Meng J, Dai X, Chang JC, et al. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 2001; 288: 203-211.
47. He J, Kuschner RA, Dewar V, Voet P, Asher LV, Vaughn DW. Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activity. Journal of Biomedical Science 2007; 14: 555-563.
48. Zhang H, Dai X, Shan X, Meng J. The Leu477 and Leu613 of ORF2-encoded protein are critical in forming neutralization antigenic epitope of hepatitis E virus genotype 4. Cellular and molecular immunology 2008; 5: 447-456.
49. Takahashi M, Hoshino Y, Tanaka T, Takahashi H, Nishizawa T, Okamoto H. Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system. Archives of Virology 2008; 153: 657-666.
50. Xing L, Wang JC, Li TC, et al. Spatial configuration of hepatitis E virus antigenic domain. Journal of Virology 2011; 85: 1117-1124.
51. Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990; 247: 1335-1339.
52. Krawczynski K, Bradley DW. Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. Journal of Infectious Diseases 1989; 159: 1042-1049.
53. Longer CF, Denny SL, Caudill JD, et al. Experimental hepatitis E: pathogenesis in cynomolgus macaques (Macaca fascicularis). Journal of Infectious Diseases 1993; 168: 602-609.
54. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. Journal of Medical Virology 2010; 82: 799-805.
55. Lee SD, Wang YJ, Lu RH, Chan CY, Lo KJ, Moeckli R. Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. Hepatology 1994; 19: 866-870.
56. Mast EE, Alter MJ, Holland PV, Purcell RH. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E virus antibody serum panel evaluation group. Hepatology 1998; 27: 857-861.
57. Ghabrah TM, Tsarev S, Yarbough PO, Emerson SU, Strickland GT, Purcell RH. Comparison of tests for antibody to hepatitis E virus. Journal of Medical Virology 1998; 55: 134-137.
58. Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Research 2011; 161: 84-92.
59. Huang W, Zhang H, Harrison TJ, Lang S, Huang G, Wang Y. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. Journal of Medical Virology 2008; 80: 824-832.
60. Guthmann JP, Klovstad H, Boccia D, et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clinical Infectious Diseases 2006; 42: 1685-1691.
61. Bryan JP, Iqbal M, Tsarev S, et al. Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan. The American Journal of Tropical Medicine and Hygiene 2002; 67: 662-668.
62. Clayson ET, Vaughn DW, Innis BL, Shrestha MP, Pandey R, Malla DB. Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. Journal of Medical Virology 1998; 54: 178-182.
63. Clayson ET, Shrestha MP, Vaughn DW, et al. Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal. Journal of Infectious Diseases 1997; 176: 763-766.
64. Rein DB, Stevens G, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55: 988-997.
65. Christensen PB, Engle RE, Hjort C, et al. Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clinical Infectious Diseases 2008; 47: 1026-1031.
66. Said B, Ijaz S, Kafatos G, et al. Hepatitis E outbreak on cruise ship. Emerging Infectious Diseases 2009; 15: 1738-1744.
67. Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362: 371-373.
68. Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 1983; 20: 23-31.
69. Khuroo MS, Saleem M, Teli MR, Sofi MA. Failure to detect chronic liver disease after epidemic non-A, non-B hepatitis. Lancet 1980; 2: 97-98.
70. Huang S, Zhang X, Jiang H, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS One 2010; 5: e13560.
71. Aggarwal R, Kini D, Sofat S, Naik SR, Krawczynski K. Duration of viraemia and faecal viral excretion in acute hepatitis E. Lancet 2000; 356: 1081-1082.
72. Li XL, Ren H, Liang XH, Zhu Y, Re XD. Detection of anti-virus antibody in sera from patients with hepatitis E after ten-year-infection. Endemic Diseases Bulletin (China) 2002; 17: 14-17.
73. Zhang JZ, Im SW, Lau SH, et al. Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. Journal of Medical Virology 2002; 66: 40-48.
74. Bendall R, Ellis V, Ijaz S, Thurairajah P, Dalton HR. Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response. Journal of Medical Virology 2008; 80: 95-101.
75. Bigaillon C, Tesse S, Lagathu G, Nicand E. Use of hepatitis E IgG avidity for diagnosis of hepatitis E infection. Journal of Virological Methods 2010; 164: 127-130.
76. Seriwatana J, Shrestha MP, Scott RM, et al. Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. Clinical and Diagnostic Laboratory Immunology 2002; 9: 1072-1078.
77. Zhuang H, Cao XY, Liu CB, Wang GM. Epidemiology of hepatitis E in China. Gastroenterologia Japonica 1991; 26(Suppl 3): 135-138.
78. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369: 1260.
79. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. Journal of Hepatology 2008; 48: 494-503.
80. Li RC, Ge SX, Li YP, et al. Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China. Emerging Infectious Diseases 2006; 12: 1682-1688.
81. Zheng Y, Ge S, Zhang J, et al. Swine as a principal reservoir of hepatitis E virus that infects humans in eastern China. Journal of Infectious Diseases 2006; 193: 1643-1649.
82. Zhang S, Wang J, Yuan Q, et al. Clinical characteristics and risk factors of sporadic Hepatitis E in central China. Virology Journal 2011; 8: 152.
83. Zhang W, He Y, Wang H, et al. Hepatitis E virus genotype diversity in eastern China. Emerging Infectious Diseases 2010; 16: 1630-1632.
84. Lu J, Zhou Y, Lin X, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4: e8467.
85. Zhu FC, Huang SJ, Wu T, et al. Sporadic hepatitis E in rural areas of eastern China: a community-based prospective study. (Under Review)
86. Zhang J, Zhang XF, Zhou C, et al. Efficacy of a recombinant vaccine against hepatitis E virus infection: a double-blinded, randomized, placebo-controlled phase 3 clinical trial. (Under Review)
87. Zhang J, Liu CB, Li RC, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27: 1869-1874.
88. Goel A, Aggarwal R. Prevention of hepatitis E: another step forward. Future Microbiology 2011; 6: 23-27.
89. Wu T, Zhu FC, Huang SJ, et al. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 2012. DOI:10.1002/hep.25522